is a frequent adverse event of cisplatin
treatment. No therapy is currently available for cisplatin
. A systematic review of experimental animal studies and in vitro experiments was conducted to evaluate gene therapy
as a potential future therapeutic option.
Eligible studies were identified through searches of electronic databases Ovid MEDLINE, Ovid MEDLINE In-Process, Embase, PubMed, Biosis Previews, Scopus, ISI Web of Science, and The Cochrane Library.
Articles obtained from the search were independently reviewed by 2 authors using specific criteria to identify experimental animal studies and in vitro experiments conducted to evaluate gene therapy
. No restriction was applied to publication dates or languages.
Data extracted included experiment type, cell type, species, targeted gene, gene expression, method, administration, inner ear site evaluated, outcome measures for cytotoxicity, and significant results.
Fourteen articles were included in this review. In vitro and in vivo experiments have been performed to evaluate the potential of gene expression manipulation for cisplatin
. Twelve different genes were targeted including NTF3
, and Ctr1
. All of the included articles demonstrated a benefit of gene therapy
on cytotoxicity caused by cisplatin
Experimental animal studies and in vitro experiments have demonstrated the efficacy of gene therapy
. However, further investigation regarding safety, immunogenicity, and consequences of genetic manipulation in the inner ear tissues must be completed to develop future therapeutic options.